Discovery and development of the anticancer agent salinosporamide A (NPI-0052)

Bioorg Med Chem. 2009 Mar 15;17(6):2175-80. doi: 10.1016/j.bmc.2008.10.075.

William Fenical ¹, Paul R Jensen, Michael A Palladino, Kin S Lam, G Kenneth Lloyd, Barbara C Potts

Affiliations

Affiliation

1 Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093-0204, USA.

PMID: 19022674 DOI: 10.1016/j.bmc.2008.10.075

Abstract

The discovery of the Anticancer agent salinosporamide A (NPI-0052) resulted from the exploration of new marine environments and a commitment to the potential of the ocean to yield new natural products for drug discovery and development. Driving the success of this process was the linkage of academic research together with the ability and commitment of industry to undertake drug development and provide the resources and expertise to advance the entry of salinosporamide A (NPI-0052) into human clinical trials. This paper offers a chronicle of the important events that facilitated the rapid clinical development of this exciting molecule.

Name
Email *

	Sorry, but the email address you supplied was invalid.